Citing concerns over patient safety, product quality, dosing accuracy, and supply chain integrity, the US Food and Drug Administration (FDA) is signaling a more aggressive regulatory posture toward the growing market for unapproved and compounded GLP-1 weight-loss products.
As demand for obesity treatments continues to grow, the agency issued a